WC
ROIV icon

Wexford Capital’s Roivant Sciences ROIV Stock Holding History

Wexford Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,000
Closed -$373K – 309
2025
Q1 		$373K Buy
+37,000
New +$400K 0.1% 138
2024
Q4 		– Sell
-21,000
Closed -$242K – 243
2024
Q3 		$242K Buy
+21,000
New +$239K 0.06% 143

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Wexford Capital's ROIV Position: Q2 2025 in Review

Wexford Capital sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 37,000 shares — an estimated $373K sold.

Wexford Capital first reported a position in ROIV in Q3 2024 and held it in 2 quarters. The position peaked at $373K in Q1 2025. 337 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

  • Wexford Capital reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 37,000 Roivant Sciences shares in Q2 2025, an estimated $373K.
  • Wexford Capital first reported a position in Roivant Sciences in Q3 2024 and held it in 2 quarters.
  • Wexford Capital's Roivant Sciences position peaked at $373K in Q1 2025.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.